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Background: Facial nerve palsy leaves people unable to move muscles on the affected side of 
their face. Challenges exist in patients accessing facial neuromuscular retraining (NMR), a 
therapy used to strengthen muscle and improve nerve function. Access to therapy could 
potentially be improved through the use of digital technology. However, there is limited 
research available on patients’ and clinicians’ views about the potential benefits of such 
telerehabilitation based on their lived experiences of treatment pathways. 
 
Objective: This study aims to gather information about facial palsy treatment pathways in the 
United Kingdom, barriers to accessing NMR, factors influencing patient adherence, measures 
used to monitor recovery, and the potential value of emerging wearable digital technology. 
 
Methods: Separate surveys of patients with facial palsy and facial therapy specialists were 
conducted. Questionnaires explored treatment pathways and views on telerehabilitation, were 
co-designed with users, and followed a similar format to enable cross-referencing of responses. 
A follow-up survey of national specialists investigated methods used to monitor recovery in 
greater detail. Analysis of quantitative data was conducted allowing for data distribution. Open-
text responses were analysed using thematic content analysis.  
 
Results: A total of 216 patients with facial palsy and 25 specialist therapists completed the 
national surveys. Significant variations were observed in individual treatment pathways. 
Patients reported an average of 3.27 (SD 1.60) different treatments provided by various 
specialists, but multidisciplinary team reviews were rare. For patients diagnosed most recently, 
there was evidence of more rapid initial prescribing of corticosteroids (prednisolone) and 
earlier referral for NMR therapy. Barriers to NMR referral included difficulties accessing 
funding, shortage of specialist therapists, and limited awareness of NMR among general 
practitioners. Patients travelled long distances to reach an NMR specialist centre; 9% (8/93) of 
adults reported traveling ≥115 miles. The thematic content analysis demonstrates positive 
attitudes to the introduction of digital technology, with similar incentives and barriers identified 
by both patients and clinicians. The follow-up survey of 28 specialists uncovered variations in 
the measures currently used to monitor recovery and no agreed definitions of a clinically 
significant change for any of these. The main barriers to NMR adherence identified by patients 




Conclusions: The study findings provide valuable information on facial palsy treatment 
pathways and views on future introduction of digital technology. Possible ways in which 
emerging sensor-based digital technology can improve rehabilitation and provide more 
rigorous evidence on effectiveness are described. It is suggested that one legacy of the COVID-
19 pandemic will be lower organizational barriers to this introduction of digital technology to 
assist NMR delivery, especially if cost-effectiveness can be demonstrated. 
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Bell palsy is an acute unilateral paralysis of the facial nerve, resulting in a patient partially, or 
completely, losing the ability to voluntarily move facial muscles on the affected side of the face 
[1]. It is the most common acute disorder affecting a single nerve, and its cause is unknown [2]. 
Each year, the condition affects 11 to 40 people per 100,000 in the population, most commonly 
in the age group of 30 to 45 years [3]. The annual incidence of Bell palsy in the United Kingdom 
is currently 37.7 per 100,000 population [4]. Bell palsy represents only approximately 60% of 
all facial nerve paralysis (FNP) cases [5]. The total number of FNP cases occurring annually in 
the United Kingdom is estimated to be at least 22,500, and 1 in 60 individuals will be affected 
over the course of their lifetime [6,7].  
 
Epidemiological studies indicate that this neurological condition occurs more commonly in 
those with diabetes, obesity, hypertension, and upper respiratory conditions and people who 
are immunocompromised or pregnant [2,6,8] or following infection by a virus such as herpes 
simplex [9]. Data from the United States show a recent rise in incidence, possibly linked to 
increasing rates of herpes infections [10]. Without intervention, some patients will show an 
element of recovery within 2 to 3 weeks and complete recovery within 3 to 4 months [2,3]. 
However, although normal facial function is completely restored in approximately 70% of 
cases, 30% will have a poor recovery [11,12] with facial disfigurement and sometimes facial 
pain [3,13], and up to 16% of those affected will have residual involuntary movements known 
as synkinesis [3]. Research shows that people with these residual deficits experience a long-
term reduction in quality of life, psychological distress, depression, and social alienation, often 
relinquishing a previous public-facing role [3,13-16]. As a result, patients with FNP continue to 
have relatively low public visibility, unless a high-profile international star reveals their own 
diagnosis [17].  
 
Available Treatments 
Although various treatments are available, uncertainty exists regarding the effectiveness of 
many of these. Cochrane systematic reviews have confirmed the effectiveness and cost-
effectiveness of corticosteroids (prednisolone) administered within 72 hours of onset of 
symptoms [18-20]. Beyond this initial treatment, for those with incomplete recovery, there are 
a number of medical options available. Various surgical procedures, together with botulinum 
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toxin injections can attempt to normalize facial appearance [21-25]. However, a Cochrane 
review of surgical interventions has reported that there is insufficient evidence to decide 
whether such procedures are beneficial and has also concluded that further trials are unlikely 
[26].  
 
Physical rehabilitation therapy can be used as an adjunct to medical treatments. The use of 
facial neuromuscular retraining (NMR) to strengthen muscle and improve nerve function has 
been evaluated more than other physical therapies [27-32]. A 2011 Cochrane review has 
concluded that there is some evidence that NMR can improve facial function (for moderate 
nerve paralysis and chronic cases) and reduce sequelae in acute cases, although it was 
recommended that both need to be confirmed in randomized controlled trials [33]. An update 
of this systematic review is currently underway [34]. A recent review of physical therapy 
combined with standard drug treatment (SDT) has reported evidence of positive effects on 
grade and time to recovery compared with SDT alone [35].  
 
Practice Guidelines and Patient Involvement 
In the context of an incomplete evidence base, current international guidelines highlight the 
need to consider patients’ experiences and preferences [2,36]. Recent clinical practice guidelines 
from the United States, which conclude that physical therapy can provide potential functional 
and psychological benefit, add that there is a “large role for shared decision making” [2]. 
Although Canadian guidelines make no recommendation regarding the use of facial NMR in 
the acute phase, owing to a lack of good quality trials and risk of bias, its use is suggested for 
patients who do not have complete facial recovery [36]. In the United Kingdom, clinical 
guidelines produced by the National Institute for Health and Care Excellence (NICE) 
recommend rapid initial medication (prednisolone) and referral to a range of hospital-based 
medical specialists [37]. Guidelines for commissioning neurology services in the United 
Kingdom also include a recommendation to consider new transformational technologies [38]. 
 
Objectives 
The potential for the “digital patient” to transform the delivery of care has been demonstrated 
in many clinical areas [39], but there is a lack of evidence for FNP. The aim of this study, 
conducted in collaboration with patients and specialist clinicians, is to gather evidence about 
FNP treatment pathways in the United Kingdom, the referral process and timing of NMR, 
current outcomes used to monitor recovery, and the potential role of digital technology to assist 
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in rehabilitation. The study was conducted as part of a research program (Facial Remote 
Activity Monitoring Eyewear [FRAME]) funded by the UK National Institute for Health 
Research (NIHR). The FRAME program aims to develop inconspicuous miniaturized sensor 
devices in spectacle frames to measure facial movement, providing biofeedback to patients and 
access for clinicians to outcome data, and to conduct early health technology assessment of the 
wearable FRAME digital technology shown in Figure 1 [40].  
 






To provide context for technology introduction, national surveys were conducted to explore 
patients’ and specialist therapists’ experiences of FNP care pathways in the United Kingdom 
and the potential role of digital technology. Separate questionnaires were co-designed for 
patients and therapists, piloted, and refined following feedback. Each questionnaire included a 
mix of closed and open-ended questions (Multimedia Appendix 1) and followed a similar format 
to enable cross-referencing of some responses [41]. Questionnaires collected demographic 
details, information on treatment pathways, and ratings of the importance of treatments 
personally experienced. Respondents were encouraged to add textual comments to expand on 
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responses to closed questions. Further open-ended questions explored the potential value of the 
emerging FRAME technology. Both questionnaires were uploaded on a web-based platform. 
 
Recruitment to National Surveys 
For patients, an open recruitment strategy was adopted to achieve geographical spread. People 
with experience of FNP were recruited in collaboration with the national charity, Facial Palsy 
UK [42]; the patient survey was advertised widely, including via social media. Recruitment of 
specialist therapists was coordinated through a nation-wide professional group, Facial Therapy 
Specialists UK [43]; all members were emailed a personal invitation containing a link to the 
questionnaire, and the initial email was followed by 2 reminders over a period of 5 months. 
 
Follow-Up Survey 
A preliminary analysis of responses uncovered a range of methods used to report treatment 
outcomes. Therefore, a further survey was conducted to examine these in greater detail, 
especially any use of validated scales, and whether there is consensus on the definition of a 
clinically significant change for these measures. A convenience sample of 50 clinicians 
attending the Facial Therapy Specialists Annual Meeting held in London (October 1, 2018) 
were invited to complete this questionnaire. 
 
Analysis of Responses 
The closed questions were analysed using SPSS (version 25, IBM Corporation). Response 
patterns were summarized using mean and SD or median and IQR, depending on data 
distribution. Certain variables were grouped to explore changes over time (e.g., time since 
diagnosis). Open-text comments expanding on responses to closed questions and text replying 
to open questions were analysed using thematic content analysis [44]. Inductive coding was used, 
following a flexible analysis approach that helped account for any further themes emerging 
during the coding process [45]. Data were coded and analysed for thematic patterns and 
meanings within the data until saturation was reached. 
 
Ethics 
Ethical approval was granted by the Health and Life Sciences Research Ethics Committee, 






Respondent Rate and Participants 
 
National Surveys 
The response rate (RR) for patients was calculated based on the number of people accessing 
the invitation link (after viewing an advertisement) versus the number of patients completing 
the questionnaire (216/216, 100% RR). Patients were resident in England (all 9 English 
regions), Scotland, Ireland, and Wales. The RR for clinicians was based on the number of UK 
therapists contacted who completed the questionnaire (25/49, 51% RR); 5 responses from 
therapists not currently practicing in the United Kingdom were excluded.  
Analysis of patient responses identified that 77.3% (167/216) of patients had acquired FNP as 
adults, 12.0% (26/216) acquired it at birth or during childhood, 7.9% (17/216) were carers of a 
child with the condition, and 2.8% (6/216) had another personal or professional connection. 
Patients with adult-acquired FNP had a mean of 6.96 (SD 7.00) years of experience since first 
being diagnosed. Table 1 shows that the most common cause of their condition reported by 
patients was Bell palsy. Specialist therapists were mainly physiotherapists by training (22/25, 
88%), with the remainder being speech and language therapists. Clinicians had a mean of 9.72 




The follow-up questionnaire was completed by 28 of 50 clinicians (RR 56%); 75% (21/28) 
were facial therapists, 11% (3/28) were hospital doctors, 8% (2/28) were neurological 
physiotherapists, and 4% (1/28) were clinical psychologists.  
 
Treatment Pathways 
An analysis of treatment pathways was conducted for patients with adult-acquired FNP. 
Respondents reported receiving an average of 3.27 (SD 1.60) different treatments following 
initial diagnosis, most commonly corticosteroids, advice on eye care, and facial NMR, as 




Table 1: UK patients with adult-acquired facial nerve paralysis: Reported diagnosis and 




Response N (%) 





Acoustic neuroma/vestibular schwannoma 
Ramsay Hunt syndrome 
Salivary gland/parotid tumour 
















Treatments provided to date 
[166 responses] 
 
Advice on eye care 




Facial neuromuscular retraining 
Electrical stimulation therapy 
Plastic surgeryb 














Stage at which first treatment started 
[164 responses] 
 
Within 72hrs following symptoms 
Within one month of onset 
1 – 6 months post-onset 
6 – 9 months post-onset 









aOther causes include: virus of brain stem, post-operative complications, otitis media, skull fracture, side-effect 
of radiotherapy, accidental injury. 
bPlastic surgery includes: face lift, brow lift, eyelid surgery, facial sling 
cOther treatments provided include: acupuncture, self-funded chiropractic and massage. 
dNo treatment group includes: 2 patients diagnosed with acoustic neuroma or vestibular schwannoma, 4 Bell’s 
palsy (1 assigned to trial control group). 
 
Diagnosis and Initial Treatment 
Overall, 66.4% (109/164) of adult-acquired cases who reported the timing of their first 
treatment said this was within 72 hours of symptom onset (Table 1); for those most recently 
diagnosed (≤1 year ago), this figure was 91% (31/34) versus 47% (32/68) for patients 
diagnosed 5 to 18 years ago. The average time to first review of their case was 64 (SD 26.8) 
days; for those diagnosed ≤1 year ago, this figure was an average of 6 (SD 28.8) days. Fewer 
than 9.6% (16/166) of patients had been referred for psychological therapy. 
 
Referral for NMR 
Of 167 respondents with adult-acquired FNP, 98 (58.6%) had been referred for facial NMR, 
and these patients were treated in 35 different centres. Table 2 shows that nearly half (44/98, 
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45%) were referred for NMR by a hospital consultant following other treatments; only 28% 
(27/98) were referred by their general practitioner (GP), and a further 14% (14/98) indicated 
that they initiated the referral themselves (usually via their GP) following information provided 
by friends, family, or patient support groups or based on their own research. Therapists reported 
that their specialist centre received a mean of 73.2 (SD 75.5) new facial NMR referrals in an 
average year, with a large variation between centres (median 30, IQR 123). Table 3 indicates 
that the mean percentage of referrals from a GP is 37% (SD 32%), with hospital consultants 
accounting for between 11% and 18%, depending on the specialty. 
 
Table 2: Patients with adult-acquired facial nerve paralysis referred for facial neuromuscular 
retraining (n=98) 
 
Patient Question Response N (%) 



































aReferral routes-Other includes: solicitor, speech and language therapist, Botox consultant. 
bFeedback tended to be given verbally, with the addition of photographic evidence, sharing of EMG results, 





Table 3: Current referral and treatment pathways reported by UK facial therapy specialists 
(n=25) 
 
Referrals Response Mean % (SD) 



















Response N (%) 
Wait for first appointment following referral 
[25 responses] 
 
< 1 week 
1 – 2 weeks 
3 – 4 weeks 
5 – 6 weeks 






Treatments patients receive before referral 
[25 responses] 
 
Advice on eye care 
Facial neuromuscular retraining 
Prednisolone or other corticosteroids 
Botox injections 
Plastic surgery 






















Feedback provided to referring clinician 
[25 responses] 
Feedback on progress and final outcome 
Feedback on final outcome only 




aOther sources of referral: community paediatricians, neurosurgical/maxillofacial consultants, physiotherapists, 
speech & language therapists. 
bOther prior treatments: blood tests, MRI, EMG, referral to peer support group, education, soft tissue 
mobilisation, facial massage, taping. 
cOther follow-on referrals: radiology, nerve conduction studies, maxillofacial, ENT, Speech and Language 
therapy, restorative dentistry, vestibular physiotherapy, audiology. 
 
Figure 2 shows that the referral for NMR occurs at different points following the onset of 
symptoms. Overall, 15% (15/98) of adult cases were referred within 1 month; 38% (8/21) of 
people diagnosed most recently (≤1 year ago), compared with 0% for those diagnosed >18 
years ago. Once referred, patients reported that they had to wait an average of 7.14 weeks 
(range 0.5-23 weeks) for a first appointment. Table 3 shows that therapy centres currently 
record a mean wait time of 4.67 (SD 3.35) weeks. One in 4 adult patients (22/97, 23%) 
described experiencing difficulties with their referral, most commonly owing to problems 
accessing National Health Service (NHS) funding, a shortage of specialist therapists, or 
difficulties in persuading their GP to refer. Overall, 80% (20/25) of centres were aware that 
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some patients experienced difficulties; the 2 main causes identified were limited awareness of 
facial NMR among GPs and a shortage of NHS funding. 
 




Therapists reported that before referral for NMR, their patients usually received a number of 
other treatments, as detailed in Table 3, most commonly corticosteroids, advice on eye care, 
Botox injections, and plastic surgery. In addition, 24% (6/25) of centres reported receiving 
referrals following failed NMR, presumably provided by a nonspecialist. On completion of 
facial NMR, 64% (16/25) of centres regularly refer some patients for psychological therapy, 
72% (18/25) to ophthalmology, and 52% (13/25) to surgery (dynamic facial reanimation). 
Although several specialties are involved in the treatment pathway, only 52% (13/25) of 
therapists had participated in a multidisciplinary team (MDT) review. Similarly, only 23.0% 
(38/165) of adult patients were aware of such a review of their case, and a further 24.8% 
(41/165) were uncertain. 
 
Views on Treatment 
When asked to rate the importance of various treatments, based on their own experience, both 
patients and therapists rated the same 6 most highly, although median scores indicated little 
discrimination among them. Patients’ scores produced the following ranking: 1st—advice on 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
1 year or less
More than 1, up to 5 years
More than 5, up to 18 years
18 years+
Total
Within 72 hours following first occurrence of symptoms
Within 1 month of onset
1-6 months post-onset
6-9 months post-onset





eye care, 2nd—facial NMR, 3rd—psychological therapy, 4th—corticosteroids, 5th—Botox 
injections, and 6th—plastic surgery. Therapists identified a similar order, although they ranked 
psychological therapy lower as 4th and surgery higher as 5th. All other treatments were rated 
as important by fewer than 4% of respondents. 
 
Adherence to NMR 
Adult patients reported varying levels of adherence to their prescribed NMR program, with 
only 33% (32/97) recording very high levels, 41% (40/97) reporting medium-to-high 
adherence, 21% (20/97) recording poor-to-medium levels, and 5% (5/97) being uncertain about 
adherence. An analysis of patients’ open-text comments identified 3 main barriers, regardless 
of the level achieved: “difficulties in fitting facial exercises into daily life,” “using a mirror 
while completing exercises,” and “insufficient regular follow-up.” Patients who reported a very 
high level of adherence described 3 further facilitating factors: “observing improved outcomes 
in self,” “belief that the treatment will work,” and “observing positive outcomes in others.” 
These patients also highlighted a common fear that acted as a spur: “scared of not recovering.” 
An analysis of comments made by the medium-to-high adherence patient group uncovered 2 
additional demotivating factors: an “inability to see any improvement” and “lack of funds to 
travel for check-ups.” In terms of travel, distances can be considerable. Although most adult 
patients (75/97, 81%) were referred to a centre within their own region, 9% (8/93) reported 
traveling ≥115 miles to reach a specialist centre. Among patients with poor-to-medium 
adherence, 2 further barriers were identifiable: “pain associated with facial exercises” and 
“exercises can be tiring”, possibly indicative of poor execution of a prescribed facial exercise 
regime. 
 
When asked to describe their patients’ level of compliance, 36% (9/25) reported very high 
levels, 56% (14/25) reported medium-to-high adherence, 4% (1/25) recorded poor-to-medium 
levels, and 4% (1/25) were uncertain about adherence. Interestingly, therapists appear to have 
underestimated the level of poor-to-medium adherence, perhaps suggesting overoptimistic 
feedback by patients. The thematic content analysis shows that therapists identify the same 3 
barriers limiting adherence (i.e., “fitting exercises into daily life,” “lack of evidence of 
improvement,” and “use of a mirror”). Unlike patients, therapists did not identify patients’ 
travel costs. However, they did additionally think that the timing of other treatments influences 
adherence, for example, “poorer adherence post-surgery because this may be viewed as the 
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primary treatment for managing their condition” and “Botox given too early may reduce 
compliance if patients rely on this to relieve feelings of tightness and synkinesis.” 
 
Feedback on Recovery 
Table 2 shows that 73% (70/96) of patients received regular feedback on their recovery during 
the course of treatment. This is provided in a number of ways with no consistent pattern 
nationally. Table 3 indicates that the regularity of feedback to referring physicians varies; 52% 
(12/25) of therapists provide feedback throughout treatment, but 40% (10/25) only report a 
final outcome. Final discharge summaries also vary, some include validated measures such as 
the Sunnybrook Scale and others provide photographs showing the patient’s progress. 
 
In response to the follow-up survey, clinicians reported the experience of using various 
methods for recording treatment outcomes ranging from photographic evidence to recognized 
disease-specific scales. When asked to name scales they had used, 17 different instruments 
were identified (Table 4). The most frequently cited was the Sunnybrook Scale (26/28, 93% of 
respondents) [46], followed by the Facial Disability Index (FDI) identified by 54% (15/28) of 
respondents [29], and the House-Brackmann (HB) Scale identified by 50% (14/28) of clinicians 
[47]. Relatively few respondents were able to define a clinically significant change for these 
measures: 27% (7/26) for Sunnybrook, 7% (1/15) for FDI, and 21% (3/14) for HB. Where 
answers were provided, there was no consensus. 
 
Digital Technology 
A thematic analysis of open-text comments on the potential value of digital technology 
identified 4 superordinate themes, as shown in Textbox 1. The first theme, System, was 
predominantly voiced by specialist therapists who highlighted the potential for this technology 
to help reduce pressure on their time, improve their ability to monitor a patient’s progress, 
increase coverage, and reduce travel for outpatient reviews. An extra subtheme, expressed by 
patients within the System theme, was that new technology could help raise medical awareness, 
especially in primary care. A second theme, Self-management, was identified by both groups. 
This focused on improving treatment adherence and emphasized factors such as enabling 
people to fit facial exercises into their daily routines and providing motivational feedback 




The third theme, Identity, emerged mainly from patients’ responses. This highlighted 
psychological benefits such as improved confidence in people who are frightened to draw 
attention to themselves and hope in individuals that their condition might improve.  
 














10 points change (4 respondents) 
≥5 points change (1 respondent) 
“5:1” change (2 respondents) 






≥5 points change (1 respondent) 









Change by 1 grade (2 respondents) 
Grade 3 eye closure or above (1 respondent) 
Not sensitive enough for therapy outcomes (2 
respondents) 






Change by 5 points (1 respondent) 
Change by 10 points (1 respondent) 
Change by 15 points (1 respondent) 










Change by 1 point (1 respondent) 
Change by 10 points (1 respondent) 
Change by 15 points (1 respondent) 
Otherc (1 respondent) 





10 points change (1 respondent) 























10 points change (1 respondent) 











No comment (1 respondent) 
aAfter the treatment score was compared with the opinion of a therapist for training or education purposes. 
bDeveloped for facial aesthetic patients, enables users to tailor a version to suit their needs based on over 40 scales 
measuring a range of concepts important to patients. 
cFACE-Gram software (MEEI, Boston, Mass). 
dComprises 10 items drawn from CORE-OM which is used in evaluation of counselling and psychological therapies in the 
UK. 
eFrench oro-facial myofunctional assessment to quantify  impairment and specify motor and functional deficit. 
fGraphic-visual adaptation of House-Brackmann facial nerve grading for peripheral facial palsy 





Textbox 1. Themes and subthemes: representative quotes from questionnaires. 









Therapist time It is a good adjunct to one-to-one therapy for most patients [Therapist] 
I think that for our patient group and geography Telerehab would work well… we have no dedicated time for facial therapy. It’s 
included as an acute treatment [Therapist]. 
Monitoring To be able to monitor a patient's progress remotely will be of great value. It also has the potential to generate and collate a lot of 
objective data on facial function which will be invaluable in efficient data collection for future research [Therapist] 
Any technology in the form of an app and use of EMG biofeedback would be massively useful. This would offer real time 
feedback about how facial muscles are performing and how successful they are in performing their exercises [Therapist] 
Access Our community colleagues I think would benefit greatly and more the patients as many travel from long distances to see the 
team here as rare specialism [Therapist] 
I am always interested in new advances in medicine. I think if it can provide cover for patients in areas where there is no 
specialism [in facial neuromuscular], then it will be invaluable [Therapist] 
These are essential for the future of intervention with this patient group especially as there are few specialists and patients are 
currently having to travel long distances [Therapist] 
Medical 
awareness 
It [technology] needs to be embraced, further developed and used to educate the medical profession about the condition, its 
treatments, causes and correct treatment regime [Patient] 







It would benefit some patients and encourage those patients who find it hard to fit exercises into their daily routine [Therapist] 
Using the 'Fitbit' technology whereby users are given rewards for exercising, can check on their daily performance and review 
weekly summaries of how well they have done. Pop up reminders to do exercises may also [be] very useful [Therapist] 
Motivation May be very useful to provide motivational feedback [Therapist] 
Technology could give users rewards for exercising, check on their daily performance and review weekly summaries of how 




Confidence Anything that can help the physical issues as well as facial symmetry/making someone feel better about themselves/more 
confident is so important [Patient] 
If facial palsy patients can be helped by the use of new technologies; they should be.  They are hardly likely to fight for 
treatment as we are traumatised, embarrassed and scared about bringing attention to themselves [Patient] 
Hope Personally, I would try whatever technology was available! [Patient] 
I am open to trying absolutely anything that could help my symptoms [Patient] 








Natural I think it's great, it's good to know there is always research into new ways to aid recovery [Patient] 
I think novel ways of assessing and treating patients using technology must be embraced [Therapist].  
I am all for new technology if it proves helpful to the patient [Patient] 
Societal benefit This is exactly what we need! We need to move forward with the times. I feel many new treatment may be expensive initially 
but if it can change a person life then it is worth it [Patient] 
In the long term it may work out cheaper … [the patient] may have their confidence back and be able to work and contribute 
back to society [Patient]  
Funding  This is a very interesting area however costing and funding within NHS would be a concern for clinical use [Therapist] 
I would like to see it made available on the NHS [Patient] 
Financial pressures on health services, the relative rarity of facial therapists, the increasing familiarity / dependence of many 




The final theme, Innovation, encompassed views, such as, that innovation is natural and that it 
can bring positive societal benefits, together with an awareness that funding constraints limit 
implementation of innovations. Patients demonstrated a great willingness to support future 
introduction of digital technology, but they also emphasized the need to raise awareness among 
GPs alongside implementation. Therapists expressed a similarly positive view of 
telerehabilitation, with a clear consensus that digital technology could not replace the initial 
face-to-face consultation because patients need to be carefully trained to be able to complete 




This exploration of the experiences of patients with facial palsy and their clinicians provides 
new information on UK treatment pathways, access to facial neuromuscular retraining, the 
methods in use to monitor recovery, and patients’ and clinicians’ views on the introduction of 
an emerging digital technology to support facial NMR. The findings highlight the need to 
understand patients’ and clinicians’ experiences before introducing such a technology. As 
funding barriers currently limit access to routine NMR, evidence of cost-effectiveness may be 
needed before implementation. 
 
Treatment Pathways 
Although variations were observed in the treatment pathways experienced by patients, there 
are signs that more recent cases (diagnosed ≤1 year ago) received treatment sooner than cases 
diagnosed >5 years ago. For the only medical treatment supported by Cochrane systematic 
reviews (rapid initial prednisolone treatment [19]), we observed high adherence by GPs, 
especially for patients diagnosed most recently (91% treated). For facial NMR therapy 
(partially supported by Cochrane review evidence [33]), this study found a move toward earlier 
NMR referrals in more recent cases. Even so, 1 in 4 patients experienced difficulties with their 
referral, commonly citing poor GP awareness. The fact that guidelines currently contain no 
firm guidance on referrals for NMR may offer some explanation [37].  
 
In the United Kingdom, NICE advises that uncomplicated FNP cases can be managed by 
primary care to include referral to various hospital medical specialists and therapists [37]. This 
is challenging because an average GP will only see one patient every 2 years [48]. An earlier 
UK study identified an overall reduction in GP referral rates of patients with FNP to hospital 
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medical specialists over the period 2001 to 2012 [4]. In this study, twice as many referrals to 
specialist facial therapists were initiated by hospital consultants compared with GP referrals, 
with patients often prompting the GP referrals. The NICE guidance for GPs does not 
specifically mention NMR referral, instead indicating a need for confirmatory trial evidence as 
suggested by the Cochrane review [33]. An update to this review may help inform future 
guidance on referrals [34]. Finally, although patients in our study ranked psychological therapy 
third highest in terms of its importance, fewer than 10% had been referred; this is presumably 
linked to the fact that NICE guidelines only contain a weak recommendation for GPs to 
consider referral for counseling [37].  
 
Once referred for NMR, access to an appropriate therapist can be problematic. Several patients 
reported traveling very long distances to reach a specialist center; the cost of travel for regular 
checkups was also identified as a barrier to adherence by patients. Specialist centers reported 
receiving patients previously referred to a nonspecialist therapist, reinforcing the need for 
increased access to appropriately trained professionals [49]. Patient adherence to prescribed 
facial exercises will influence treatment effectiveness. Both patients and therapists identified 
the same barriers: fitting exercises into daily life, the use of a mirror, and the need for regular 
feedback. The fact that clinicians perceive higher levels of adherence than those reported by 
patients indicates a need for improved monitoring of adherence. Other research has shown that 
a collaboration between specialists can reduce the burden of long-term disability for acute onset 
FNP [50]. In this study, although patients experienced care pathways that involved referral to 
several medical specialties, such collaboration was limited; just over half (52%) of the 
therapists had any experience of participating in an MDT review, and only 23% of adult 
patients were aware of such a review of their case. Interestingly, reports are now emerging of 
efforts to integrate physical therapy with treatment by ophthalmologists, oculoplastic surgeons, 
and ENT and other specialists [51]. It is also considered that MDTs are likely to play an 
important role in standardizing outcome measures and implementing relevant data collection 
[52]. 
 
Evidence of effectiveness of FNP treatments currently remains reliant on subjective measures, 
including reduction in crocodile tears, incomplete recovery of motor function, and cosmetically 
disabling sequelae [19,33]. This study identified inconsistency in the methods used in the United 
Kingdom to report treatment outcomes. In addition to photographs, various validated scales are 
used. Among these, the Sunnybrook Scale, mentioned by 96% of specialists, is considered to 
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grade patients in a more objective and continuous manner than the HB Scale, which was 
mentioned by half [53]. However, FDI, mentioned by 54% of clinicians, better represents 
impairment, disability, and psychosocial status than the 36-item Short Form Survey (SF-36) 
health status measure, mentioned by 14% [54]. In addition to variation in the scales used to 
record treatment outcomes, there was no consensus on what represents a clinically significant 
change in any scale. 
 
Interestingly, very few clinicians (14%) reported the experience of using EuroQol-5D, the 
health-related quality of life (HRQoL) measure used for NHS reimbursement decisions [55]. 
Converted into incremental quality-adjusted life years (QALYs), this is used to quantify long-
term treatment outcomes [56]. QALYs are particularly relevant as 30% of patients with FNP 
will continue to live with reduced HRQoL over the rest of their lives [3,13-15]. In addition, 
because such individuals may give up their original employment [57], this can lead to a 
significant long-term societal cost burden, especially if the condition was acquired in early life 
[58]. An international collaboration has recently been established, focusing on pediatric patients 
with FNP (using a patient-centered approach, similar to this study) with the aim of comparing 
FNP treatment pathways, standardizing outcome measurement, and developing value-based 
reimbursement strategies [59].  
 
Digital Technology 
To our knowledge, this is the first UK study to explore the potential use of wearable digital 
technology to support facial NMR therapy. The findings show that patients and therapists both 
demonstrate a positive attitude toward the introduction of such technology, with patients 
recognizing benefits centered on better self-management and improved confidence, therapists 
identifying better monitoring of patients’ progress and reduced work pressures, and both 
highlighting the potential for improved adherence to facial exercise programs. The main 
barriers to adherence could all be addressed by an appropriate real time (synchronous) digital 
solution that addresses patients’ and clinicians’ feedback. A review of telerehabilitation articles 
has recently concluded that patients’ feedback will help improve future areas of applications, 
although no FNP telerehabilitation studies were identified [60]. A review of real time, web-
based consultation has highlighted a number of general barriers and facilitators [61]. The key 
barriers and facilitators mirror those found in this study. Asynchronous methods for monitoring 
FNP treatment outcomes have also recently been evaluated by 2 research teams. Tan et al [62] 
reported that the assessment of videos using the Sunnybrook and HB scales is as good as a 
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face-to-face assessment, although the lack of real time interaction was judged to limit the value 
of this approach. Mothes et al [63] found that automatic Sunnybrook grading of photographs 
using machine learning can deliver fair agreement compared with the subjective rating of the 
same photographs. Neither study addressed real time monitoring and biofeedback. 
 
Limitations 
A number of limitations should be borne in mind when considering this research. First, patient 
respondents may not be representative of the wider population because participants were 
recruited via a specialist support group. Second, there may be recall inaccuracy when 
participants are asked to provide information sometime after the event. Third, the therapist RR 
(51% national survey and 56% follow-up survey) means that data may not fully reflect the 
national picture. Finally, although the greatest care was taken in the questionnaire design, as 
with all surveys that record individuals’ views, the validity and reliability of the data could not 
be tested independently. 
 
Conclusions and Implications for Technology Introduction 
To date, little research has explored the potential value of digital technology in assisting facial 
NMR therapy. This study provides a baseline overview of FNP treatment pathways in the 
United Kingdom, the factors limiting access to NMR and influencing therapy adherence, the 
main methods used to record treatment outcome, and the potential role of digital technology. 
The study indicates that harmonization of outcome measures is required to both strengthen the 
evidence on treatment effectiveness and to better support MDT management. The main factors 
limiting NMR adherence could all be addressed through the use of real time digital technology. 
However, for the type of wearable technology being considered, product design will be an 
additional factor likely to influence adherence [64], especially in the younger 30- to 45-year 
age group affected by this condition [3]. However, although the study clearly demonstrates 
positive attitudes toward the introduction of digital technology, economic barriers may prove 
to be a challenge. Previous research has identified funding as a barrier for access to surgical 
treatments for FNP in England [65] and more recently in Wales, Scotland, and Northern Ireland 
[66]. This study has similarly identified funding barriers to NMR referral. Finally, 
organizational and cultural factors are acknowledged to act as important barriers to 
implementation for all digital health innovations [67], often reinforced by policy priorities [68]. 
One legacy of the COVID-19 pandemic is that health systems worldwide are rapidly adopting 
digital options in many clinical areas [69]. Thus, barriers to the introduction of digital 
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technology to assist facial NMR therapy may now be lower, especially if cost-effectiveness 
can be demonstrated. 
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Multimedia Appendix 1 – National Survey Questionnaires 
 
1. Patient Questionnaire  
Facial Palsy – Introduction of Digital Technology 
Facial palsy affects approximately 22,500 people annually in the UK, with the cumulative number of cases since 
2000 totalling over one third of a million.  Although seventy per cent of cases will achieve complete recovery, it 
is estimated that the number of people living life with some level of disability during this period is 115,000, 
including 63,500 with a permanent deficit of facial function   
 
Facial palsy affects both men and women equally, occurring most commonly in people aged between 15 and 60 
years, but the condition is commoner in those who are pregnant, have diabetes, or conditions such as 
hypertension, sarcoidosis and HIV infection.  It is estimated that for the 63,500 with a permanent disability, poor 
recovery leads to the loss of two quality adjusted life years (QALYs) per person. 
 
Current treatment options for facial palsy 
Currently, oral corticosteroids (Prednisolone) within 72 hours of onset of symptoms are the only treatment 
recommended by NICE, with strong evidence that this can improve outcome and shorten time to recovery.  A 
series of systematic Cochrane reviews have examined the evidence on other surgical and physical treatments.  
The 2011 Cochrane review of tailored facial exercises concluded that there is some evidence they can help 
improve outcome and reduce sequelae; further randomised controlled trials were recommended.  We are 
currently updating this 2011 review to identify further published trials of facial exercise therapy. 
 
The FRAME study (Facial Remote Activity Monitoring Eyewear) 
A major study has been funded by NIHR i4i programme to develop a digital technology which could improve 
access & outcomes for patients referred for facial exercise therapy: see [LINK provided]. 
 
National Survey 
As part of the FRAME study, we are undertaking a national survey to gather evidence on current treatment 
pathways for facial palsy patients and the place of facial exercise therapy.  Various groups are being surveyed to 




We would be very grateful if you would help us by completing this online survey, answering all the questions 
applicable to you and giving as much detail as possible.  A pilot indicates that this should take approximately 15 
minutes to complete. 
 
Please feel free to give any additional information or feedback at the end of the survey. All information you give 
us will remain anonymous and no information will be used which could identify you personally.  If you have 
any questions or would like to talk about the survey, please contact [LINK provided].  We would also be happy 
to hear any additional thoughts or comments you may have. 
 
Thank you very much for your help.  Your support is very much appreciated and the more of you who reply, the 
more your opinions and experiences can be incorporated into our research. 
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Q 1: Your connection to facial palsy (please tick one only):  
 
I am a parent/carer of a child under 18 with facial palsy  
I was born with facial palsy  
I acquired facial palsy during childhood 
I am an adult with acquired facial palsy 
I am a health professional with an interest in facial palsy 
Another personal connection to facial palsy (e.g. partner, sibling, friend)  
 
 
Q 2: Your experience of facial palsy:  
 
Q2.1 How many years’ experience of facial palsy do you have? 
 Enter number 
 
Q2.2 At what stage were you (or your relative/friend) first reviewed by a 
health professional? 
 Approximate time after first occurrence (please specify) 
 
Q2.3 What was the cause of the facial palsy (if known)? 
  Don’t know 
  Acoustic neuroma/vestibular schwannoma 
  Bell’s palsy 
  Birth trauma 
  Congenital facial palsy 
  Facial nerve neuroma 
  Lyme disease 
  Moebius syndrome 
  Neurofibromatosis type 2 (NF2) 
  Ramsay Hunt syndrome 
  Salivary gland/parotid tumour 
  Stroke 





Q2.4 At what stage did you (or your relative) first receive treatment 
(please tick only one)? 
  Within 72 hours following first occurrence of symptoms 
  Within 1 month of onset 
  1-6 months post onset 
  6-9 months post onset 
  More than 9 months post onset 
  Other (please specify)   
 
Q2.5 Which of the following treatments have been provided to date 
(please tick as many as apply)? 
  Prednisolone or other corticosteroids 
  Antivirals 
  Antibiotics 
  Advice on eye care 
  Botox injections 
  Plastic surgery e.g. face lift, brow lift, eyelid surgery, facial sling 
  Facial exercise therapy 
  Electrical stimulation therapy 
  Psychological therapy e.g. CBT 
  Other (please specify)   
 
Q2.6 Has a multidisciplinary clinic for facial palsy patients ever 
discussed this case? 
  Yes 
  No 






Q 3: Your experience of facial exercise therapy: 
 
Q3.1 Have you (or your relative) ever been referred for facial exercise 
therapy? 
  Yes 
  No (If No, please go to Q4) 
 
Q3.2 Who referred you/ your relative for facial exercise therapy? 
  My General practitioner (GP) 
  Surgeon 
  Neurologist 
  ENT Specialist 
  Other (please specify)   
 
Q3.3 At what point did a referral for facial exercise therapy take place? 
  Within 1 month following first occurrence of symptoms 
  1-6 months post onset 
  6-9 months post onset 
  More than 9 months post onset 
  Other (please specify)   
 
Q3.3 To which centre was the referral for facial exercise therapy? 
  Birmingham 
  Chelmsford Essex 
  Glasgow Royal Infirmary 
  Liverpool 
  London Guys Hospital 
  London Queens Square 
  Manchester Lindens Clinic (NHS funded) 
  Newcastle 
  Norwich 
  Oxford 
  QVH East Grinstead 
  Southampton 




Q3.3 How long was the wait for an appointment, once referred? 
 Enter number of weeks 
 
Q3.4 Were there any problems being referred for facial exercise 
therapy? 
  No 
  Yes (If Yes, please expand below) 
 
 




Q3.5 Was feedback provided during facial exercise therapy on level of 
improvement? 
  No 
  Yes (Please expand below) 
 
 




Q3.6 How would you describe your (or your relative’s) adherence to the 
facial exercise programme? 
  Very high 
  Medium to high 
  Poor to medium 
  Don’t know 
 
 






Q3.7 Was facial therapy offered in conjunction with any other treatment 
(please tick as many as apply)? 
 
  Botox injections 
  Electrical stimulation therapy 
  Other (please specify)   
 
Q 4: In your view, how important is it for the NHS to provide the 
following treatments for people with facial palsy [on a scale from 1 
(very low value) to 10 (very high value)]: 
(Please enter your rating for treatments where you have some experience – you 






Corticosteroids   
Antivirals   
Antibiotics   
Advice on eye care   
Botox injections   
Plastic surgery1   
Facial exercise therapy   
Psychological therapy2   
Other (please specify) 
 
  
1 Includes face lift, brow lift, eyelid surgery, facial sling 
2 Includes cognitive behavioural therapy (CBT) 
 
Q 5: Where do you live in the UK? 
  London 
  South East England 
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  East of England 
  South West England 
  West Midlands 
  East Midlands 
  Yorkshire and the Humber 
  North West England 
  North East England 
  Scotland 
  Wales 
  Northern Ireland 
  Other (please specify)   
 
 
Q 6: Thank you very much for your valuable contribution to this 
study.  
Q6.1 We may wish to contact you for further details following this 
questionnaire. Please let us know whether you are willing to participate 
in a telephone interview? (all responses would be confidential and 
anonymous)? 
  No 
  Yes (If Yes, please provide details below) 
 
Please provide your contact details - e-mail address (this will not be retained 












Thank you for taking the time to complete our survey. 
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Multimedia Appendix 1 (contd) 
2. Clinician Questionnaire  
Facial Palsy – Introduction of Digital Technology 
Facial palsy affects approximately 22,500 people annually in the UK, with the cumulative number of cases since 
2000 totalling over one third of a million.  Although seventy per cent of cases will achieve complete recovery, it 
is estimated that the number of people living life with some level of disability during this period is 115,000, 
including 63,500 with a permanent deficit of facial function   
 
Facial palsy affects both men and women equally, occurring most commonly in people aged between 15 and 60 
years, but the condition is commoner in those who are pregnant, have diabetes, or conditions such as 
hypertension, sarcoidosis and HIV infection.  It is estimated that for the 63,500 with a permanent defect, poor 
recovery leads to the loss of two quality adjusted life years (QALYs) per patient. 
 
Current treatment options for facial palsy 
Currently, oral corticosteroids (Prednisolone) within 72 hours of onset of symptoms are the only treatment 
recommended by NICE, with strong evidence that this can improve outcome and shorten time to recovery.  A 
series of systematic Cochrane reviews have examined the evidence on other surgical and physical treatments.  
The 2011 Cochrane review of tailored facial exercises concluded that there is some evidence they can help 
improve outcome and reduce sequelae; further randomised controlled trials were recommended.  We are 
currently updating this 2011 review to identify further published trials of facial exercise therapy. 
 
The FRAME study (Facial Remote Activity Monitoring Eyewear) 
A major study has been funded by NIHR i4i programme to develop a digital technology which could improve 
access & outcomes for patients referred for facial exercise therapy: see [LINK provided]. 
 
National Survey 
As part of the FRAME study, we are undertaking a national survey to gather evidence on current treatment 
pathways for facial palsy patients and the place of facial exercise therapy.  Several groups are being surveyed to 
include facial therapy specialists, medical staff (GPs, surgeons, hospital physicians) and patients. 
 
Your contribution 
We would be very grateful if you would help us by completing this online survey, answering all the questions 
applicable to you and giving as much detail as possible.  A pilot indicates that this should take approximately 15 
minutes to complete. 
 
Please feel free to give any additional information or feedback at the end of the survey. All information you give 
us will remain anonymous and no information will be used which could identify you personally.  If you have 
any questions or would like to talk about the survey, please contact [LINK provided].  We would also be happy 
to hear any additional thoughts or comments you may have. 
 
Thank you very much for your help.  Your support is very much appreciated and the more of you who reply, the 






Q 1: Your clinical background (please tick one only):  
 
I am a Facial Therapy Specialist with the following training: 
  Physiotherapist 
  Speech & Language Therapist (SLT) 
  Occupational Therapist 
  Other (please specify)   
 
Other involvement in facial palsy (please specify)   
 
 
Q 2: Your experience of treating facial palsy:  
 
Q2.1 How many years’ experience of treating facial palsy do you have? 
 Enter number 
 
Q2.2 In an average year, APPROXIMATELY how many new patients 
are assessed by your team for facial therapy? 
 Enter number 
 
Q2.3 When you first see a new patient, have they received any of the 
following treatments prior to referral to you (please tick as many as 
apply)? 
  Prednisolone or other corticosteroids 
  Advice on eye care 
  Botox injections 
  Plastic surgery e.g. face lift, brow lift, eyelid surgery, facial sling 
  Facial exercise therapy 
  Psychological therapy e.g. CBT 




Q2.4 Which of the following do you regularly provide for patients 
(please tick as many as apply)? 
  Advice/ education about facial palsy 
  Massage, stretching, trigger point release, relaxation 
  EMG biofeedback, taping 
  Eye care, mouth care 
  Neuromuscular retraining 
  Botox clinics 
  Synkinesis delinking exercises 
  Other (please specify)   
 
Q2.5 Which of the following do you refer your patients for (please tick as 
many as apply)?  
  Opthalmology 
  Botox injections 
  Surgery for dynamic facial reanimation 
  Psychological therapy e.g. CBT 
  Other (please specify)   
 
Q2.6 Do you ever participate in a multidisciplinary clinic for facial palsy 
patients? 
  Yes 
  No 
 
Q 3: Your experience of facial exercise therapy referrals: 
 
Q3.1 From which of the following areas do you receive referrals for 
facial exercise therapy (please tick as many as apply)? 
  South East – London 
  South East England 
  East of England 
  South West England 
  West Midlands 
  East Midlands 
  Yorkshire and the Humber 
  North West England 
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  North East England 
  Scotland 
  Wales 
  Northern Ireland 
  Other (please specify)   
 
Q3.3 On average, how long do patients wait for their first appointment, 
once referred to you for assessment? 
 Enter number of weeks 
 
Q3.4 Have patients encountered problems in being referred for facial 
exercise therapy 
  No 
  Yes (If Yes, please expand below) 
 
 




Q3.5 At what stage are patients usually referred for facial exercise 
therapy (please tick as many as apply)? 
  Within 1 month following first occurrence of symptoms 
  1-6 months post onset 
  6-9 months post onset 
  More than 9 months post onset 
  Other (please specify)   
 
Q3.6 What percentage of your patients are referred by the following 
(only a rough estimate is required)? 
 General practitioner (GP) 





 Other (please specify)   
 
 
3.7 Do you routinely provide feedback to GPs or other medical staff 
monitoring progress and outcomes for patients during facial exercise 
therapy? 
  No 
  Yes Final Outcome only (Please expand below) 
  Yes Progress & Final Outcome (Please expand below) 
 
 








Q3.8 How would you describe patients’ level of compliance with their 
facial exercise programme? 
  Very high 
  Medium to high 
  Poor to medium 




Please briefly describe reasons for your answer, any changes over time 













Q 4: In your view, how important is it to provide the following 
treatments for patients with facial palsy [on a scale from 1 (very low 
value) to 10 (very high value)]: 
(Please enter your rating for treatments where you have some experience – you 





Corticosteroids   
Advice on eye care   
Botox injections   
Plastic surgery1   
Facial exercise therapy   
Psychological therapy2   
Other (please specify) 
 
  
Other (please specify) 
 
  
Other (please specify) 
 
  
1 Includes face lift, brow lift, eyelid surgery, facial sling 
2 Includes cognitive behavioural therapy (CBT) 
 
Q 5: What is your work location in the UK: 
 
  Birmingham 
  Liverpool 
  London Guys Hospital 
  London Queens Square 
  Norwich 
  Oxford 
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  QVH East Grinstead 
  Southampton 
  Other (please specify)   
 
Q 6: Thank you very much for your valuable contribution to this 
study.  
Q6.1 We may wish to contact you for further details following this 
questionnaire. Please let us know whether you are willing to participate 
in a telephone interview? (all responses would be confidential and 
anonymous)? 
  No 
  Yes (If Yes, please provide details below) 
 
Please provide your contact details - e-mail address (this will not be retained 

















Thank you for taking the time to complete our survey. 
 
